MiMedx Group Launches Axiofill

MiMedx Group Inc., a transformational placental biologics company, has launched Axiofill, an Extracellular Matrix (ECM) Particulate product derived from human placental tissue.
 
Axiofill is a human placental-derived particulate product available for Surgical Recovery procedures. It offers a competitive advantage over other xenograft, or animal-based, particulate products that undergo aggressive processing techniques to eliminate potential antigens.
 
The existing market for xenograft products, including particulates, is estimated at $230 million. Axiofill provides a cost-effective human collagen scaffold that is conducive for use in large, complex wounds and those of irregular geometries. It may be applied directly as a dry particulate, or with the addition of saline, as a paste depending upon surgeon preference and clinical need.
 
“The launch of Axiofill is particularly significant for MiMedx,” said Rohit Kashyap, Ph.D., MiMedx president, Wound Care & Surgical. “We have added another new product to our portfolio that is designed for the needs of the Surgical Recovery market, enhancing the value we provide to customers. As the first human placenta-derived ECM particulate, we believe that Axiofill offers a distinct advantage over other particulate products and provides impressive clinical utility for physicians treating complex surgical wounds. Importantly, we continue to execute on our customer needs-driven innovation roadmap and view Axiofill as a strong platform for future product innovation.”
 
“When considering treatment options to address significant tissue defects, physicians have a persistent need for a versatile product that conforms to a variety of complex wound configurations, whether an uneven surface defect or a deep, tunneling wound,” said Dr. Susan Hagen, general surgeon, Boulder, CO. “I believe Axiofill offers a safe, convenient and powerful tool that can be used in a wide variety of surgical applications.”
 
Axiofill is processed using a proprietary PURION technique that preserves the natural tissue microstructure. The resulting biocompatible scaffold retains key structural proteins, including type I and type IV collagen, laminin, and fibronectin.
 
John Harper, Ph.D., MiMedx chief technology officer, senior vice president of Research and Product Development, added, “The scientific work we have done to characterize Axiofill highlights its role as a provisional scaffold that supports key regenerative processes, including cellular infiltration and neovascularization needed for the generation of site-appropriate functional tissue. MiMedx remains dedicated to developing novel products that address areas of unmet clinical need.”

Related News